These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 27352931

  • 1. ASXL1 plays an important role in erythropoiesis.
    Shi H, Yamamoto S, Sheng M, Bai J, Zhang P, Chen R, Chen S, Shi L, Abdel-Wahab O, Xu M, Zhou Y, Yang FC.
    Sci Rep; 2016 Jun 29; 6():28789. PubMed ID: 27352931
    [Abstract] [Full Text] [Related]

  • 2. Role of Plasma Gelsolin Protein in the Final Stage of Erythropoiesis and in Correction of Erythroid Dysplasia In Vitro.
    Han SY, Lee EM, Kim S, Kwon AM, Baek EJ.
    Int J Mol Sci; 2020 Sep 27; 21(19):. PubMed ID: 32992584
    [Abstract] [Full Text] [Related]

  • 3. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.
    Wang J, Li Z, He Y, Pan F, Chen S, Rhodes S, Nguyen L, Yuan J, Jiang L, Yang X, Weeks O, Liu Z, Zhou J, Ni H, Cai CL, Xu M, Yang FC.
    Blood; 2014 Jan 23; 123(4):541-53. PubMed ID: 24255920
    [Abstract] [Full Text] [Related]

  • 4. Epigenetic regulation by ASXL1 in myeloid malignancies.
    Yang FC, Agosto-Peña J.
    Int J Hematol; 2023 Jun 23; 117(6):791-806. PubMed ID: 37062051
    [Abstract] [Full Text] [Related]

  • 5. Loss of ASXL1 triggers an apoptotic response in human hematopoietic stem and progenitor cells.
    Hilgendorf S, Folkerts H, Schuringa JJ, Vellenga E.
    Exp Hematol; 2016 Dec 23; 44(12):1188-1196.e6. PubMed ID: 27616637
    [Abstract] [Full Text] [Related]

  • 6. [Role of ASXL1 mutation in myeloid malignancies].
    Sheng MY, Zhou Y, Xu MJ, Yang FC.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug 23; 22(4):1183-7. PubMed ID: 25130853
    [Abstract] [Full Text] [Related]

  • 7. Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.
    Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T, Kagiyama Y, Kawabata KC, Nakahara F, Izawa K, Oki T, Maehara A, Isobe M, Tsuchiya A, Harada Y, Harada H, Ochiya T, Aburatani H, Kimura H, Thol F, Heuser M, Levine RL, Abdel-Wahab O, Kitamura T.
    J Clin Invest; 2013 Nov 23; 123(11):4627-40. PubMed ID: 24216483
    [Abstract] [Full Text] [Related]

  • 8. Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms.
    Collins TB, Laranjeira ABA, Kong T, Fulbright MC, Fisher DAC, Sturgeon CM, Batista LFZ, Oh ST.
    Exp Hematol; 2024 Apr 23; 132():104178. PubMed ID: 38340948
    [Abstract] [Full Text] [Related]

  • 9. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
    Hu Z, Hu S, Ji C, Tang Z, Thakral B, Loghavi S, Medeiros LJ, Wang W.
    Leuk Res; 2018 Feb 23; 65():25-28. PubMed ID: 29288910
    [Abstract] [Full Text] [Related]

  • 10. A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies.
    Inoue D, Fujino T, Sheridan P, Zhang YZ, Nagase R, Horikawa S, Li Z, Matsui H, Kanai A, Saika M, Yamaguchi R, Kozuka-Hata H, Kawabata KC, Yokoyama A, Goyama S, Inaba T, Imoto S, Miyano S, Xu M, Yang FC, Oyama M, Kitamura T.
    Leukemia; 2018 Jun 23; 32(6):1327-1337. PubMed ID: 29556021
    [Abstract] [Full Text] [Related]

  • 11. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
    Lin Y, Zheng Y, Wang ZC, Wang SY.
    Hematology; 2016 Sep 23; 21(8):454-61. PubMed ID: 27077763
    [Abstract] [Full Text] [Related]

  • 12. Impaired erythropoiesis after haemorrhagic shock in mice is associated with erythroid progenitor apoptosis in vivo.
    Robinson Y, Matenov A, Tschöke SK, Weimann A, Oberholzer A, Ertel W, Hostmann A.
    Acta Anaesthesiol Scand; 2008 May 23; 52(5):605-13. PubMed ID: 18419713
    [Abstract] [Full Text] [Related]

  • 13. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, Haferlach T, Schnittger S.
    Leukemia; 2013 Sep 23; 27(9):1852-60. PubMed ID: 23628959
    [Abstract] [Full Text] [Related]

  • 14. ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation.
    Saika M, Inoue D, Nagase R, Sato N, Tsuchiya A, Yabushita T, Kitamura T, Goyama S.
    Sci Rep; 2018 Oct 26; 8(1):15873. PubMed ID: 30367089
    [Abstract] [Full Text] [Related]

  • 15. The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes.
    Verbeek W, Vehmeyer K, Wörmann B, Hiddemann W.
    J Cancer Res Clin Oncol; 1995 Oct 26; 121(6):338-42. PubMed ID: 7797598
    [Abstract] [Full Text] [Related]

  • 16. Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia.
    Cui Y, Tong H, Du X, Li B, Gale RP, Qin T, Liu J, Xu Z, Zhang Y, Huang G, Jin J, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z.
    Exp Hematol Oncol; 2015 Oct 26; 4():14. PubMed ID: 26019984
    [Abstract] [Full Text] [Related]

  • 17. SPARC promotes the development of erythroid progenitors.
    Luo Z, Luo P, Yu Y, Zhao Q, Zhao X, Cheng L.
    Exp Hematol; 2012 Oct 26; 40(10):828-36. PubMed ID: 22687753
    [Abstract] [Full Text] [Related]

  • 18. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R.
    Eur J Haematol; 2005 Dec 26; 75(6):485-91. PubMed ID: 16313260
    [Abstract] [Full Text] [Related]

  • 19. ASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1.
    Rohatgi N, Zou W, Collins PL, Brestoff JR, Chen TH, Abu-Amer Y, Teitelbaum SL.
    Blood Adv; 2018 Oct 09; 2(19):2467-2477. PubMed ID: 30266822
    [Abstract] [Full Text] [Related]

  • 20. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
    Gelsi-Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, Finetti P, Murati A, Arnoulet C, Zerazhi H, Fezoui H, Tadrist Z, Nezri M, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D.
    Br J Haematol; 2010 Nov 09; 151(4):365-75. PubMed ID: 20880116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.